Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ligilactobacillus salivarius MP101
- Development stage
- Preclinical
- Lead developer
- Complutense University of Madrid
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Ligilactobacillus salivarius MP101 is a specific probiotic strain of live bacteria investigated for its immunomodulatory properties. Developed by researchers at the Universidad Complutense de Madrid, it has been studied as a supportive care intervention for COVID-19 in elderly nursing home residents. The strain is administered orally, typically via a dairy vehicle, and aims to modulate the immune microenvironment by influencing levels of pro-inflammatory cytokines and immune mediators such as IL-8, IL-31, BAFF, and TNF receptors. It is classified as a live biotherapeutic or probiotic and currently exists as a research-stage compound rather than an approved pharmaceutical drug.
- Other names
- Ligilactobacillus salivarius MP101L. salivarius MP101
02
Targets
BAFF (Tumor necrosis factor ligand superfamily member 13B)IL31 (IL-31)IL8 (C-X-C Motif Chemokine Ligand 8)SPP1 (Osteopontin)TNFSF13 (APRIL)TNFRSF1A (Tumor necrosis factor receptor superfamily member 1A)TNFR2 (Tumor necrosis factor receptor superfamily member 1B)
Beyond the preview
Go deeper on Ligilactobacillus salivarius MP101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ligilactobacillus salivarius MP101.